A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Completed · Phase 2 · NCT02141282
Conditions: Chronic Lymphocytic Leukemia
At a glance
- Research payments reported, 2025
- $1,965
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 127
About the trial
- Sponsor
- AbbVie (with Roche-Genentech)
- Tested
- Venetoclax (drug)
- Dates
- Started 2014-09-10; completion 2021-12-22
- Results posted
- Yes
This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.
From ClinicalTrials.gov, last updated 2022-12-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1,965 in research payments for this study in 2025 (1 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $1,965
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.